Received Feb 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
my mother died two days after she received the vaccine; This serious case was reported by a consumer via interactive digital media and described the occurrence of death in a female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, 2 days after receiving Arexvy, the patient experienced death (Verbatim: my mother died two days after she received the vaccine) (serious criteria death and GSK medically significant). The reported cause of death was death. It was unknown if the reporter considered the death to be related to Arexvy. The company considered the death to be unrelated to Arexvy. Additional Information: GSK Receipt Date: 03-FEB-2026 This case was reported by the daughter/ son of patient via interactive digital media. The reporter did not believe anything about the man-made COVID-19 virus. He/she believed it had been used as a genocide against our older people. The reporter's mother (patient) had died two days after she had received the vaccine, and reporter believed that millions more had been included in this. The batch number was not provided, and unable to contact the reporter. The case had been linked with case US2026AMR017435 reported by same reporter.; Sender's Comments: A case of Death, 2 days after receiving Arexvy, in a a female patient .Based on the available information, a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow up has not been received. US-GSK-US2026AMR017435:same reporter; Reported Cause(s) of Death: Death